Bruce Downey - Momenta Pharmaceuticals Independent Director
Director
Mr. Bruce L. Downey is Independent Director of the Company. Mr. Bruce L. Downey was a director since June 2009 and has served as chairman of our board of directors since June 2018. Mr. Downey has served as a partner at NewSpring Capital, a VC firm, since April 2009. Previously, Mr. Downey was chairman and chief executive officer of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company that operated in more than 30 countries worldwide and was acquired by Teva Pharmaceutical Industries Ltd. in 2008. Mr. Downey is a member of the board of directors of Melinta Therapeutics and Cardinal Health, Inc., serving at Cardinal on the audit and nominating and corporate governance committees, as well as privately held companies. Mr. Downey graduated with honors from Miami University in 1969 and received his law degree, cum laude, from Ohio State University since 2009.
| Age | 70 |
| Tenure | 15 years |
| Phone | 617 621-0431 |
| Web | www.momentapharma.com |
Momenta Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (30.56) % which means that it has lost $30.56 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (64.36) %, meaning that it created substantial loss on money invested by shareholders. Momenta Pharmaceuticals' management efficiency ratios could be used to measure how well Momenta Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 37.09 M in liabilities with Debt to Equity (D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. Momenta Pharmaceuticals has a current ratio of 6.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Momenta Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Momenta Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Momenta Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Momenta to invest in growth at high rates of return. When we think about Momenta Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| John Bevan | BlueScope Steel Limited | 60 | |
| Cecil Moore | NL Industries | 81 | |
| Deborah McKeithanGebhardt | Sensient Technologies | 62 | |
| Fabio Spina | Gerdau SA ADR | 52 | |
| Idalene Kesner | Olympic Steel | 60 | |
| Ralph Ratta | Olympic Steel | 64 | |
| Daniel Grollo | BlueScope Steel Limited | 46 | |
| Hank Brown | Sensient Technologies | 78 | |
| Alfredo Huallem | Gerdau SA ADR | 66 | |
| Scott Morrison | Sensient Technologies | 58 | |
| Richard Hutchinson | BlueScope Steel Limited | N/A | |
| John Harper | NL Industries | 59 | |
| Lloyd Jones | BlueScope Steel Limited | 64 | |
| Ewen Crouch | BlueScope Steel Limited | 61 | |
| Sharad Jain | Sensient Technologies | 61 | |
| Ernest Nicolas | Avient Corp | 43 | |
| Terry Worrell | NL Industries | 69 | |
| Mario Ferruzzi | Sensient Technologies | 46 | |
| Joseph Carleone | Sensient Technologies | 75 | |
| Penny BinghamHall | BlueScope Steel Limited | 57 | |
| Howard Goldstein | Olympic Steel | 65 | |
Management Performance
| Return On Equity | -64.36 | |||
| Return On Asset | -30.56 |
Momenta Pharmaceuticals Leadership Team
Elected by the shareholders, the Momenta Pharmaceuticals' board of directors comprises two types of representatives: Momenta Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Momenta. The board's role is to monitor Momenta Pharmaceuticals' management team and ensure that shareholders' interests are well served. Momenta Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Momenta Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Bennett Shapiro, Independent Director | ||
| James Anderson, Senior Vice President - Pharmaceutical Sciences | ||
| Craig Wheeler, CEO and President and Executive Director | ||
| Georges Gemayel, Director | ||
| Matthew Ottmer, COO | ||
| Alejandra Carvajal, Chief Legal Officer, General Counsel and Secretary | ||
| Elizabeth Stoner, Independent Director | ||
| Michelle Robertson, CFO, Principal Financial Officer and Principal Accounting Officer | ||
| John Bishop, Senior Vice President - Pharmaceutical Sciences | ||
| JoseCarlos GutierrezRamos, Director | ||
| Bruce Leicher, Senior Vice President General Counsel, Secretary | ||
| James Sulat, Independent Chairman of the Board | ||
| Corey Fishman, Director | ||
| Jim Anderson, Senior Vice President - Pharmaceutical Sciences | ||
| Santiago Arroyo, Senior Vice President Development and Chief Medical Officer | ||
| James Roach, Senior Vice President - Development, Chief Medical Officer | ||
| Young Kwon, Senior Vice President - Corporate Development and Strategy | ||
| Bruce Downey, Independent Director | ||
| JoAnn Beltramello, Senior Vice President - Human Resources | ||
| Steven Gilman, Director | ||
| Anthony Manning, Senior Vice President - Research | ||
| Marsha Fanucci, Independent Director | ||
| Ganesh Kaundinya, Co-Founder, Chief Scientific Officer and Sr. VP of Research | ||
| Ian Fier, Senior Vice President - Program and Project Management | ||
| Richard Shea, CFO, Sr. VP and Treasurer | ||
| Michael Franken, President - Biosimilars Business, Senior Vice President | ||
| Thomas Koestler, Independent Director | ||
| Scott Storer, CFO, Senior Vice President |
Momenta Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Momenta Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -64.36 | |||
| Return On Asset | -30.56 | |||
| Operating Margin | (815.34) % | |||
| Current Valuation | 5.71 B | |||
| Shares Outstanding | 118.97 M | |||
| Shares Owned By Insiders | 0.98 % | |||
| Shares Owned By Institutions | 99.02 % | |||
| Number Of Shares Shorted | 5.41 M | |||
| Price To Earning | (7.85) X | |||
| Price To Book | 15.41 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
Other Consideration for investing in Momenta Stock
If you are still planning to invest in Momenta Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Momenta Pharmaceuticals' history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |